These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28199375)

  • 21. Is deployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso.
    Alagna R; Combary A; Tagliani E; Sawadogo LT; Saouadogo T; Diandé S; Ouedraogo F; Cirillo DM
    BMC Infect Dis; 2021 Apr; 21(1):346. PubMed ID: 33849486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
    Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP
    PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study.
    Huang H; Zhang Y; Li S; Wang J; Chen J; Pan Z; Gan H
    Microb Drug Resist; 2018 Jun; 24(5):675-679. PubMed ID: 29053085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.
    Raizada N; Sachdeva KS; Swaminathan S; Kulsange S; Khaparde SD; Nair SA; Khanna A; Chopra KK; Hanif M; Sethi GR; Umadevi KR; Keshav Chander G; Saha B; Shah A; Parmar M; Ghediya M; Jaju J; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(10):e0140375. PubMed ID: 26469691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.
    van Kampen SC; Susanto NH; Simon S; Astiti SD; Chandra R; Burhan E; Farid MN; Chittenden K; Mustikawati DE; Alisjahbana B
    PLoS One; 2015; 10(6):e0123536. PubMed ID: 26075722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Xpert
    Beste J; Mutaquiha C; Manhiça I; Jose B; Monivo C; Faria M; Creswell J; Codlin AJ; Michel C; Wagenaar B; Gloyd S; Cowan J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1358-1365. PubMed ID: 30355417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
    Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
    BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
    Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
    Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance and impact of routinely implemented Xpert® MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine.
    Nikolayevskyy V; Kontsevaya I; Nikolaevskaya E; Surkova E; Samchenko S; Esipenko S
    Clin Microbiol Infect; 2019 Aug; 25(8):1040.e1-1040.e6. PubMed ID: 30590114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.
    Lawn SD; Brooks SV; Kranzer K; Nicol MP; Whitelaw A; Vogt M; Bekker LG; Wood R
    PLoS Med; 2011 Jul; 8(7):e1001067. PubMed ID: 21818180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.
    Jacobson KR; Barnard M; Kleinman MB; Streicher EM; Ragan EJ; White LF; Shapira O; Dolby T; Simpson J; Scott L; Stevens W; van Helden PD; Van Rie A; Warren RM
    Clin Infect Dis; 2017 Jun; 64(11):1502-1508. PubMed ID: 28199520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.